Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

CAMBRIDGE, Mass., June 18, 2007 - Genzyme Corp. (Nasdaq: GENZ) today announced the results of two new studies comparing a powder form of Renvela™ (sevelamer carbonate) to Renagel® tablets (sevelamer hydrochloride), including one trial in which patients received the powder form three times per day, and one in which it was administered once per day.

Genzyme is developing Renvela in powder form to provide an additional option for patients with chronic kidney disease in managing their phosphate levels. A New Drug Application for Renvela tablets is already on file with the FDA, and previous studies have shown that the tablet formulation provides equivalent phosphate control to Renagel in patients on dialysis and significant phosphorus control in patients with chronic kidney disease who are not on dialysis. Today’s results are the first from trials comparing the efficacy of the powder form of Renvela to Renagel tablets.

In the first powder trial, patients treated with the powder form of Renvela three times per day experienced equivalent phosphorus control to patients treated with Renagel tablets three times per day. As a result, this trial successfully met its primary endpoint.

In the second trial, patients dosed with the powder form of Renvela once per day and those treated with Renagel tablets three times per day achieved statistically significant reductions in serum phosphorus, with both groups reaching target levels for phosphorus control outlined in the K/DOQI treatment guidelines. Phosphorus levels in the Renagel arm (4.6 mg/dL) were lower than those in the Renvela arm (5.3 mg/dL), and this trial did not achieve its primary endpoint of demonstrating non-inferiority of Renvela powder dosed once per day to Renagel tablets dosed three times per day.

In both trials, the safety profile of Renvela was consistent with the previous clinical experience of patients on dialysis
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... division of Wyeth (NYSE: WYE ), today ... has granted Fast Track designation,to the Company,s investigational ... is seeking a pediatric indication for,active immunization against ... serotypes included in the vaccine. The vaccine includes ...
... Targeting a Cure, WASHINGTON, May 28 ... join meso patients, caregivers,loved ones and advocates to ... at the Mesothelioma Applied Research Foundation,s,International Symposium on ... 28 at the Hyatt Regency on Capitol Hill, ...
Cached Medicine Technology:Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 3Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 4International Symposium on Malignant Mesothelioma 2008 2
(Date:7/10/2014)... Adults with dyslexia are more likely to report that ... people who don,t have the learning disorder, according to ... to 10 percent of people, causes problems with reading ... with this condition said they suffered physical abuse during ... dyslexia. "Even after accounting for age, race, sex ...
(Date:7/10/2014)... News) -- Men who have a vasectomy may be ... study suggests. But the risk is comparatively small, ... the study said more research is needed to determine ... the study, Harvard researchers analyzed data from more than ... starting in 1986. During that time, 6,023 cases of ...
(Date:7/10/2014)... that the "Mississippi Baby," believed to have been functionally ... detectable levels of the virus, the Elizabeth Glaser Pediatric ... remains hopeful that the scientific breakthrough that allowed the ... two years will continue to help researchers understand how ... , "Although we had high hopes that the child ...
(Date:7/10/2014)... cells captured with a microchip-based device developed at the ... and the MGH Cancer Center can be cultured to ... In the July 11 issue of Science ... cells accurately reflect a tumor,s genetic mutation over time ... now can culture cells from the blood that represent ...
(Date:7/10/2014)... "Mississippi baby" an infant seemingly cured of HIV that ... of HIV infection in The New England Journal of ... more than two years of not taking antiretroviral therapy without ... researchers involved in the case. , "Certainly, this ... the medical staff involved in the child,s care, and the ...
Breaking Medicine News(10 mins):Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3
... , BREWER, Maine, Nov. 24 Thanks to an innovative ... Anthem Blue Cross and Blue Shield in Maine, some Anthem ... physician without leaving home. , As part of the ... and questions and communicate via email with their provider about ...
... pediatric cancer and hematology patients in medical rounds benefits ... a new Indiana University School of Medicine study. ... conducted, is now one of only a small number ... cancer and hematology patients the opportunity to join their ...
... ... available to discuss the recently proposed cosmetic surgery tax. , ... Arlington Heights, IL (Vocus) November 24, 2009 ... available to discuss the recently proposed cosmetic surgery tax., , ,WHAT: Some of ...
... strains have increased sevenfold, study finds, , TUESDAY, ... infections normally found in the community are increasingly ... that inpatients could become infected, new research says. ... sevenfold increase in the incidence of outpatients with ...
... New York personal injury ... attorney after a heavy metal piece falls off a plane and lands in a local Long ... New York, NY (PRWEB) ... recent occurrence as a reminder that everyone should have the number of a personal injury attorney ...
... ... seminar series, new ways to train doctors in providing proven, non-surgical relief to millions ... ... ) announced the first three 2010 Frozen Shoulder Syndrome Diagnosis & Treatment seminar ...
Cached Medicine News:Health News:The Doctor Will See You Now. . .Online 2Health News:Involving family in medical rounds benefits both family and medical team 2Health News:Involving family in medical rounds benefits both family and medical team 3Health News:Involving family in medical rounds benefits both family and medical team 4Health News:Leading Plastic Surgery Experts Available to Discuss Proposed ,Cosmetic Surgery Tax 2Health News:MRSA Creeping Into Hospitals From the Outside 2Health News:MRSA Creeping Into Hospitals From the Outside 3Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 2Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 3Health News:OTZ Announces 2010 Frozen Shoulder Syndrome Seminar Schedule 2Health News:OTZ Announces 2010 Frozen Shoulder Syndrome Seminar Schedule 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: